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Abstract:  Salivary gland carcinomas constitute a rare 
but deadly group of head and neck cancers, but timely 
diagnosis is often delayed due to inherent variability in 
etiology, heterogeneity and histopathological 
characterization. SIBLINGs are a family of secreted 
glycophosphoproteins that include osteopontin (OPN), 
bone sialoprotein (BSP), dentin sialophosphoprotein 
(DSPP), dentin matrix protein-1 (DMP-1), and matrix 
extracellular phosphoglycoprotein (MEPE). SIBLINGs 
were first discovered in bone and teeth, and were 
considered to be exclusively expressed in mineralized 
tissue. In addition to mineralized tissue, SIBLINGs have 
now been shown to have variable expression in normal, 
non-mineralized tissue and in cancers. However, there 
have been no studies evaluating SIBLING expression in 
human salivary gland cancers. Our study tested the 
hypothesis that SIBLINGs, specifically, BSP, DSPP and 
OPN, would be significantly overexpressed in human 
salivary gland cancer. We also hypothesized that the 
cancer secretome would influence SIBLING expression 
in normal salivary gland cells. Methods: Normal and 
cancerous human salivary gland tissue obtained from the 
NDRI were processed using routine 
immunohistochemistry techniques to evaluate expression 
of BSP, DSP, and OPN. In addition normal HSG cell line 
and cancer HTB-41 cell line were evaluated using 
immunofluorescence techniques to localize expression of 
BSP, DSP and OPN. Normal HSG, cancer HTB-41 and 
HSG* cells (normal HSG cells exposed to a cancer HTB-
41 secretome) were propagated using routine cell culture 
techniques for 24, 48, and 72 hours. Western blotting 
techniques were utilized ii to quantify and compare 
SIBLING protein expression levels in HSG, HTB-41 and 
HSG* cells. Normal HSG, cancer HTB-41, and HSG* 
cells were processed via immunoflourescence in order to 
observe localization of SIBLINGs. Results: 
Immunohistochemistry and western blot showed 
increased expression of SIBLINGs in human salivary 
gland cancers. Furthermore, immunoflourescence 
revealed distinct localization of SIBLING proteins in 
HSG and HTB-41 cell lines. In terms of HSG*, it was 
found that cells exposed to cancer secretome exhibited 
similar SIBLING expression to HTB-41. Conclusion: 
Our studies confirm that SIBLING proteins are 
selectively expressed in human salivary gland cancer. 
Also, the cancer secretome is found to affect SIBLING 
expression in normal cells, similar to HTB-41 cancer cell 
lines. 
Keywords: small integrin-binding ligand, n-linked 
glycoproteins (siblings), human salivary gland 
cancer 
Introduction 
Salivary gland cancers, while rare, are a group of 
exceedingly fatal cancers characterized by 
abnormal growth of salivary gland cells. Salivary 
gland cancer is a rare malignancy that can occur in 
the major or minor salivary glands (Di Palma and 
Guzzo, 1993; Gillespie et al., ; Guzzo et al.). 
Salivary cancers are a histologically diverse group 
of tumors with varying prognosis and treatment 
according to grade, histology, and stage. 
Treatment is primarily surgical, with postoperative 
radiotherapy for patients with a poor prognosis 
(Lang et al., 2005a; Mazeron et al., 2003; Medina, 
1998). Treatment options are limited due to 
delayed diagnoses, complex histopathology and 
rarity (Lang et al., 2005b). Thus, salivary gland 
research is crucial to identify options for 
diagnostic and therapeutic options. 
Malignant tumors are characterized by 
uncontrollable growth and replication, with 
possibility of metastasis. Many growth factors, 
cytokines, and glycoproteins play pivotal roles in 
the regulation of proliferation, survival, growth, 
adhesion, and migration of neoplastic or abnormal 
cells (Rangaswami et al., 2006a, , 2006b). One 
group of proteins thought to play a role in 
regulating or aiding in tumor growth and survival 
are the Small Integrin Binding N-Linked 
Glycoproteins (SIBLINGs). SIBLING proteins 
were first discovered in the mineralized matrices of 
bone and teeth. The SIBLING gene family, located 
on chromosome 4, is composed of 5 members: 
osteopontin (OPN), bone sialoprotein (BSP), dentin 
sialophosphoprotein (DSPP), dentin matrix protein 
1 (DMP1), and matrix extracellular 
phosphoglycoprotein (MEPE) (Bellahcene et al., 
2008). Moreover, this family of proteins is an 
emerging group that cancer cells use to facilitate 
tumor progression. SIBLINGs are soluble, secreted 
proteins that can additionally act as modulators of 
cell adhesion through their interaction with cell 
surface receptors, such as integrins (Bellahcene et 
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al., 2008; Ogbureke and Fisher, 2004, , 2007; 
Ogbureke et al.). Although initially thought to be 
associated only with mineralized compartments of 
bone and teeth, all five SIBLING family members 
have subsequently been found in specific soft 
tissues, including metabolically active ductal 
epithelial cells (e.g., sweat glands and kidneys) as 
well as in many different types of human cancer 
(Bellahcene et al., 2008). Studies, such as the one 
by Ogbureke and Fisher in 2005, have reported 
SIBLING expression, along with their respective 
matrix metalloprotinase partners, in normal human 
salivary glands (Ogbureke and Fisher, 2005). 
Researchers have also found SIBLINGs to be 
involved in tumor progression and metastasis by 
interacting with several integrins and CD44 to 
mediate cellular signaling (Bellahcene et al., 2008). 
However, limited studies have evaluated OPN, 
BSP, and DSPP expression exclusively in salivary 
gland cancer. With little known about the SIBLING 
family and their expression in cancerous states of 
salivary gland tissues, the current study will give 
insight into SIBLING expression in salivary gland 
cancer, specifically OPN, BSP, and DSP, a cleaved 
functional protein of DSPP previously shown to 
play a role in cancerous tissues (Figure 1). While 
DSPP is a key player in tooth development and 
mineralization in odontoblast, DSP is a specific 
marker for differentiation of odontoblast with little 
known about its functionality. Therefore, with little 
information within the literature, DSP is a pivotal 
protein to study in terms of cancer and its role. 
While OPN and BSP have been evaluated in 
cancers such as colon and breast, no studies have 
evaluated SIBLING expression in salivary gland 
cancer. 
 
Fig. 1. Cleavage of dentin sialophosphoprotein into 
functional proteins DPP, 
Previous studies have demonstrated OPN 
localization within the cytoplasm of both acinar 
and ductal cells of mouse salivary glands. It was 
also established that osteopontin mRNA was found 
to be highly expressed in salivary gland tissue 
(Oates et al., 1996). Although these findings have 
been represented, the function of OPN in salivary 
glands still remains unclear, as well as its 
localization and role in human salivary gland 
carcinoma. Ogbureke and Fisher (2004) have 
demonstrated co-expression of SIBLING proteins 
and their matrix-metalloproteinase partner (MMP) 
within salivary glands (Ogbureke and Fisher, 
2004). Like OPN, BSP has been found to be 
expressed within acinar cells and the ductal system 
of salivary gland tissues (Ogbureke and Fisher, 
2007). DSP, unlike BSP and OPN, has not been 
found to be expressed in acinar cells of the salivary 
gland. With this information characterizing salivary 
gland tissue and SBILING expression, localization 
of OPN, BSP, and DSP, within salivary gland cells, 
has not yet been characterized. 
According to the National Cancer Institute at the 
NIH, the cancer microenvironment can be defined 
as, “the normal cells, molecules, and blood vessels 
that surround and feed a cancer cell”. A cancer can 
alter its microenvironment, and the 
microenvironment can affect how cancer 
progresses 
http://www.cancer.gov/dictionary?cdrid=561725. 
The secretome is the collection of all 
macromolecules secreted by a cell, and is a vital 
aspect of cell–cell communication in eukaryotes. 
In cancer, tumor cells often have secretomes with 
altered composition compared to the normal tissue 
from which they are derived. These changes can 
contribute to the acquisition and maintenance of 
the recognized hallmarks of cancer. In addition, 
there is growing evidence that the tumor secretome 
has significant implications for malignant disease 
progression. Collectively, evidence from the 
current literature suggests that the tumor 
secretome, consisting of factors derived from 
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cancer stem cells, non-stem cells and the 
surrounding stroma, is critical in cancer 
progression, and may constitute a key therapeutic 
target in many cancers (Chang et al., ; Chenau et 
al., 2009; Lin et al., ; Paltridge et al., ; Pavlou and 
Diamandis, ; Ralhan, ; Xue et al., 2008). 
Salivary gland cancer cells are capable of self-
renewal and exhibit the ability to produce 
heterogeneous populations of cancer cells. Secreted 
molecules are key mediators in cell-cell 
interactions and influence the cross talk with 
surrounding tissues. Mimicking the tumor 
environment using salivary gland cancer secretome, 
or a secreted pool of proteins from a population of 
salivary gland cancer cells, is suggested as a 
method for identifying potential therapeutic targets. 
Strong evidence exists in support of crucial cellular 
functions such as proliferation, differentiation, 
communication, and migration, cellular functions 
that can be heavily regulated by the cell secretome. 
 
Hypothesis 
The current study tested the hypothesis that 
SIBLINGs, specifically OPN, BSP, and DSP, are 
significantly overexpressed in human salivary 
gland cancer, and that the salivary gland cancer 
secretome would influence BSP and DSP 
expression in normal salivary gland cells. 
Specific Aims 
Aim 1: To determine expression of OPN, BSP, 
and DSP in normal and cancerous human 
salivary gland tissues and cell lines. Using 
immunohistochemistry, OPN, BSP and DSP 
expression was evaluated in normal and cancer 
human salivary gland tissue. Using 
immunofluorescence techniques, OPN, BSP and 
DSP were localized in normal HSG and cancer 
HTB-41 cell lines. 
Aim 2: To determine expression levels of OPN, 
BSP and DSP in normal and cancerous human 
salivary gland cell lines. Using western blot 
assays expression levels of OPN, BSP and  DSP 
were evaluated in human normal HSG and 
cancer HTB-41 cell lines. 
Aim 3: To evaluate if the cancer secretome derived 
from human salivary gland cancer cells would 
influence expression of OPN, BSP and DSP in 
normal human salivary gland cells. Using 
immunofluorescence and western blotting 
techniques, the influence of cancer secretome on 
expression of OPN, BSP and DSP in normal 
human salivary gland cells was investigated. 
Significance of the Problem 
Cancer cells are known to exhibit increased 
proliferation that allows uncontrolled growth of 
the tumor at the primary site. In addition, cancer 
cells have the ability to migrate and invade the 
surrounding tissue, a critical property that allows 
cancer cells to enter the lymphatic system or 
blood stream, resulting in metastasis to distant 
organs. Consequently, cancer progress ion and 
metastasis is the most common reason for 
fatalities in cancer patients. Salivary gland (SG) 
cancers are a rare but occasionally fatal variety of 
head and neck cancers. It is estimated that one 
adult out of 100,000 will be diagnosed with SG 
cancer each year and survival rates depend on the 
type of tumor, stage of cancer at diagnosis and 
metastasis. Although SG cancer boasts 5-year 
survival rates of 91%, this is true only if the 
cancer is diagnosed before metastasis. Survival 
rates drop to 75% with lymph node involvement, 
and 39% with metastasis. Survival of patients 
diagnosed with SG cancers is thus comparable to 
breast cancer (72% and 22%). The rarity of SG 
cancers, coupled with an inadequate 
understanding of cancer progression, has had an 
adverse effect on designing strategic therapies. 
Our data reveal that a family of proteins called 
SIBLINGs is overexpressed in human SG 
cancers. Specifically OPN, BSP and DSP are 
upregulated in human salivary gland cancers. In 
addition, our study provides evidence that the 
secretome derived from human salivary gland 
cancer cells has a significant influence on growth 
of and expression of OPN, BSP and DSP in 
normal human salivary gland cancer cells. 
Further understanding of the role of these specific 
SIBLING proteins, as well as the role of the 
secretome in cancer progression will help us 
design viable methods for early diagnosis and 
effective interventions in patients. 
Review of literature 
Salivary glands are a major exocrine glandular 
system, which aid in maintaining homeostasis of 
the oral cavity, and function to secrete saliva to 
assist the digestive and immune systems. Human 
salivary glands can be divided into two groups 
known as major and minor salivary glands. While 
the major group of salivary glands includes the 
parotid, submandibular, and sublingual glands, the 
minor group is made up of numerous small salivary 
glands which line the upper aerodigestive tract 
(Humphrey and Williamson, 2001). Anatomical 
locations of salivary glands differ, with the parotid 
gland situated along the posterior surface of the 
mandible, the submandibular gland bound by the 
inferior edge of the mandible and digastric muscle, 
and the sublingual gland lying within the anterior 
floor of the mouth and lateral to the mandible 
(Figure 2) 
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Fig. 2. Anatomical location of human major salivary glands, parotid, submandibular and 
sublingual glands.  
Salivary glands are derived from epithelial cells 
and are made up of parenchyma and stroma. 
Histology of saliva glands includes acinar cells 
(mucous and serous), ducts (striated, excretory, 
and intercalated), and myoepithelial cells. Acini 
are responsible for secreting proteins necessary 
for producing saliva. Between the epithelial cells 
and basal lamina are the myoepithelial cells, 
responsible for contraction of muscle in order to 
force saliva through the salivary gland. The acini 
secrete salivary components into the intercalated 
ducts, which then empty into the striated ducts. 
Parotid glands are the largest salivary glands in 
the human body, and are located around the 
mandibular ramus. The parotid gland secretes 
saliva through a duct, called Stensen’s duct, into 
the oral cavity. Stensen’s duct arises from the 
anterior of the parotid gland and penetrates 
through the buccinator muscle, allowing the duct 
to open into the oral cavity. In terms of histology, 
the parotid gland consists of striated and 
intercalated ducts, which are lined with columnar 
epithelium and cuboidal epithelial cells, 
respectively. Parotid gland function is defined by 
secretion of salivary alpha-amylase (sAA). By 
producing sAA, the parotid gland assists in 
decomposition of starches, such as amylose and 
amylopectin, and also prevents bacterial binding 
to oral surfaces. 
Submandibular salivary glands  are divided into 
lobes known as superficial and deep lobes, 
separated by the mylohoid muscle which forms the 
floor of the oral cavity. Secretions produced by the 
submandibular glands are emptied through 
Wharton’s duct into the floor of the oral cavity. The 
sublingual glands lie anterior to the submandibular 
glands, inferior to the tongue and are also located in 
the floor of the mouth. The sublingual glands are 
fairly small glands. Parotid secretions are mainly 
serous, sublingual gland secretions are 
predominantly mucous, and submandibular gland 
exhibits a mixed sero-mucous secretion. 
The main function of saliva, produced by the 
salivary glands, is to aid in digestion, taste, tooth 
maintenance, and immunity. Normally, the pH of 
saliva is between 6.0 and 7.2, meaning it is slightly 
acidic, which allows it to aid in digestion and food 
lubrication (Humphrey and Williamson, 2001). 
Lubrication of food particles during chewing 
allows for ease in swallowing and travel through 
the esophagus. Saliva contains a digestive enzyme, 
known as α-amylase, or ptyalin, whose function is 
to convert starch into maltose, maltotriose, and 
dextrins (Almeida et al., 2008). Furthermore, minor 
salivary glands located in the tongue secrete lingual 
lipase, which breaks down triglycerides (Humphrey 
and Williamson, 2001). Tooth maintenance is 
regulated with the help of saliva through the 
processes of demineralization and remineralization. 
Specifically, saliva influences the pH of plaque and 
acts as a buffer to inhibit formation of caries 
(Humphrey and Williamson, 2001). On another 
note, in terms of immunity, saliva is capable of 
producing secretory IgA, IgM, and IgG. IgA when 
active is capable of neutralizing viruses and 
inhibiting bacterial attachment to host tissue 
(McNabb and Tomasi, 1981). Another saliva 
component, lactoferrin, is produced by intercalated 
duct cells and can bind ferric iron. Binding iron is a 
crucial process for the human body in order to 
inhibit bacteria from consuming iron necessary for 
viability. 
One of the major pathologies that affect salivary 
glands is salivary gland carcinoma. Salivary gland 
carcinoma is a rare form of cancer, with about 3000 
new cases diagnosed annually. Due to variability in 
histological presentation between cancer types, 
treatment options are limited to surgical resections 
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and/or radiotherapy. Additionally, many salivary 
gland tumors exhibit features that make 
differentiation of malignant and benign tumors 
difficult to distinguish (Seethala, 2009). A major 
setback associated with salivary gland cancer is 
that tumors associated with salivary gland cancers 
have a high incidence of local recurrence despite 
aggressive treatment approaches. While there are 
many different types of salivary gland cancer, the 
most common are mucoepidermoid carcinoma, 
adenoid cystic carcinoma, acinic cell carcinoma, 
adenocarcinoma, and squamous cell carcinoma 
(Seifert and Donath, 1976a, , 1976b; Seifert et al., 
1977; Seifert et al., 1976; Takata et al., 1987). 
Adenocarcinoma, a main focus for tissue 
processing in this study, is classified as an 
intrinsically high-grade, or high-risk cancer. 
Overall, salivary gland cancer effects salivation in 
the oral cavity due to changes in cell morphology 
in acini formation, ducts, and epithelial cells. 
Therefore, it is critical to identify potential protein 
markers that can be used as diagnostic or 
therapeutic targets to manage salivary gland 
cancers. The current study thus focused on 
evaluating OPN, BSP and DSP as potential markers 
of salivary gland cancers. 
Previous studies have shown that SIBLING 
expression in cancers such as breast, colon, 
stomach, ovary, lung, thyroid, kidney, pancreas, 
and prostate, influence cell growth, cell adhesion, 
and cell migration during tumor progression. 
According to previous studies, SIBLINGs bind to 
cell surface integrins and sometimes CD44 in 
normal tissues, and function as signal transducers 
for cell adhesion, motility and survival through 
activating kinase cascades and transcription 
factors. The SIBLING family, located on 
chromosome 4, is defined as a soluble RGD motif 
containing integrin-binding ligands that distinguish 
them from large extracellular proteins. In cancer 
progression, adhesive properties of the SIBLINGs 
have been investigated in the context of bone 
targeting and recognition by metastasizing cancer 
cells. SIBLING molecules have also been 
implicated in enhancing the affinity of metastatic 
cancer cells for bone. Furthermore in cancer, 
SIBLINGs are bound by cancerous cells and affect 
cancer proliferation (Bellahcene et al., 1996a; 
Bellahcene et al., 2008; Bellahcene et al., 1997; 
Brown et al., 1994; Chaplet et al., 2003; Chaplet et 
al., 2006; Fisher et al., 2004; Furger et al., 2001; 
Hayashi et al., 2007; Jain et al., 2009; Ogbureke et 
al., ; Ogbureke et al., 2007; Ogbureke et al., ; 
Waltregny et al., 1998). 
Osteopontin (OPN) is an extracellular matrix 
protein produced by osteoblasts and is capable of 
stimulating many cell activities through its 
multiple receptors. Additionally, osteopontin is 
found to be synthesized at the highest levels in 
bone and epithelial tissue (Denhardt and Guo, 
1993). Specifically, an important structural 
characteristic of OPN its glycine-arginine-glycine-
aspartate-serine (GRGDS or RGD) amino acid 
sequence (Hayashi et al., 2007; Scatena et al., 
2007) (Hsieh et al., ; McKee et al.). OPN acts as a 
substrate for thrombin and tissue transglutaminase, 
thus, its function in promoting cell adhesion and 
migration is substantially enhanced when it is 
cleaved by thrombin (Furger et al., 2001). 
Therefore, the primary structure of OPN defines 
its role in calcification and mineralization control, 
cell signaling, and chemotaxis (Hsieh et al.). 
Furthermore, OPN engages with specific integrins 
to prevent apoptotic cell death through activation 
of the nuclear factor ƙB (NF-ƙB) (Furger et al., 
2001; Tuck et al., 2001). Osteopontin (OPN) is an 
extracellular matrix protein produced by 
osteoblasts and is capable of stimulating many cell 
activities through its multiple receptors. OPN can 
promote adhesion of T-cells and possibly amplify 
a CD3-mediated proliferative response. Moreover, 
OPN is regulated by many transcription factors, 
cytokines, and growth factors. In pathological 
conditions, OPN expression in induced, allowing 
the SIBLING member to facilitate cancer 
progression, metastasis, and tumorigenesis (Hsieh 
et al.). A limited number of papers have 
documented OPN expression in normal salivary 
glands, pleomorphic adenomas, and in unspecified 
malignant tumors (Brown et al., 1992; Brown et 
al., 1994). Overall, OPN is involved in adhesion, 
chemoattraction, and immunomodulation within 
normal tissue conditions. However, in malignancy, 
OPN is found to be overexpressed in many forms 
of cancer, when induced by supplementary factors, 
and aids in promoting growth of the primary 
tumors (Chabas, 2005; Chen et al., 1993b; Chen et 
al., 2008; El-Tanani et al., 2006; Fisher et al., 
2001; Furger et al., 2001; Hayashi et al., 2007; 
Jain et al., 2009; Kolb et al., 2005; Lee et al., 
2007; Pritchett et al., ; Rangaswami et al., 2006b; 
Razzouk et al., 2002; Zhang et al., ; Zhang et al., 
2000). 
Bone sialoprotein (BSP), is a sialic acid rich, 
phosphorylated glycoprotein, which is secreted 
and part of the non-collagenous extracellular 
organic matrix in human bone. BSPis responsible 
for mediating cell attachment and regulating bone 
formation. It is thought that BSP may mediate the 
targeting and attachment of normal and 
metastasizing cells to the bone surface. In cancer, 
BSP has also been found to form mineral 
crystallization, thus causing cell damage 
(Bellahcene et al., 1998; Bellahcene et al., 1997; 
Bianco et al., 1991; Chen et al., 1993a; Chen et 
al., 2003; Chen et al., 1998; Chen et al., 1992; 
Chen et al., 1991; Fedarko et al., 2001; Fisher et 
al., 2004; Fisher et al., 2001; Malaval et al., 2008; 
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Ogbureke et al., ; Ogbureke and Fisher, 2004, , 
2005, , 2007; Wang et al.) . 
Dentin sialoprotein (DSP) is another SIBLING 
member which represents about 8% of the non-
collagenous proteins in the dentin extracellular 
matrix of teeth and is a single mRNA transcript. 
DSPP is cleaved into dentin sialoprotein (DSP) 
and dentin phosphoprotein (DPP), also known as 
phosphophoryn. DSP, the amino-terminal part of 
DSPP, is a sialic acid-rich, glycosylated protein 
(Butler et al., 2002; Chen et al., 2008; Fisher, ; 
George et al., 1999; Ogbureke and Fisher, 2004, , 
2005, , 2007; Suzuki et al., ; Trueb et al., 2007; 
Zhang et al.). Similar to OPN and DSP, BSP also 
plays critical roles in progression and metastasis 
of various epithelial cancers (Fisher et al., 2004; 
Jain et al., 2009).\Evaluation of SIBLINGs in 
salivary gland cancer has not been studied before. 
However, previous studies have evaluated OPN, 
BSP, DSP, and DMP1 in various organs and 
tissues such as the breast, kidney, colon, and 
others. Table 1 provides an overview of 
SIBLING expression in various normal and 
cancerous human tissues. 
Organ/T issu e  OPN  BSP  DSPP 
 Normal
*
 Cancer
1
 Normal
*
 Cancer
1
 Normal
*
 Cancer
1
 
       
Bone High High High High Low ND 
Breast Low High Low High ND ND 
       
Lung No High Low High Low High 
Colon Low High Low High Low Low 
       
Kidne y High High High ND High ND 
Pancreas No High Low High ND ND 
       
Prosta te No High No High Low High 
       
Table 1. SIBLING expression levels in evaluated organs/tissues. Low expression of SIBLINGs usually 
exists in normal organs/tissues with exception to bone and kidneys. Moreover, SIBLING expression is 
found to be high in many tumorous organs/tissues. 
*
Defines expression of specific 
The presence of high abundance or overexpressed 
proteins hinders the detection of tumor-specific 
biomarkers, which are usually at very low 
concentrations in normal states. With this 
knowledge, biomarker studies have been 
concentrated on analysis of the "secretome." The 
secretome is meant to describe the proteins 
released by a cell into the extracellular space, thus 
playing a role in cellular processes such as cell 
signaling and motility. 
Tumor progression is characterized by tumor cell 
interaction with its extracellular environment, 
thus creating favorable conditions for growth and 
metastasis. Many cell-cell interactions are 
mediated by proteins within the secretome. 
Therefore, the cancer secretome can be described 
as constituting proteins released from tumor 
cells. Proteins secreted from malignant cells 
prove to be an auspicious source of serological 
biomarkers, due to their ability to enter the blood 
circulation (Chang et al., ; Chenau et al., 2009; 
Lin et al., ; Paltridge et al., ; Pavlou and 
Diamandis, ; Xue et al., 2008). 
The cancer secretome is a valuable source for 
biomarkers, not only in that secreted proteins 
are indicators of the physiological conditions 
of the cells at any time point, but also because 
they have the highest likelihood of entering the 
blood circulation. Therefore, it is important to 
evaluate HTB-41 secretome and the presence 
of SIBLING proteins. Additionally, assessment 
of the cancer secretome and its effects on 
normal cell growth is imperative to the 
understanding of biological protein influences 
within the cancer secretome. 
Methods 
Human Cell Lines: The current study used two 
human cell lines, (i) normal human salivary gland 
cells, HSG (received as a generous gift from Dr. 
Baum B, NIH, Bethesda, MA), and (ii) human 
salivary gland cancer cells, HTB-41 (ATCC, 
Manassas, VA). HSG cells were aseptically 
cultured in DMEM/F-12 media (Corning Cellgro, 
Manassas, VA), supplemented with 10% FBS and 
1% penicillin-streptomycin-amphotericin. HTB-
41 cells were aseptically cultured in McCoys5A 
media (Corning Cellgro, Manassas, VA), 
supplemented with 10% FBS and 1% penicillin-
streptomycin-amphotericin. All cells were 
maintained in a 5% CO2 atmosphere at 37°C. 
Cancer Secretome Collection: HSG and HTB-41 
cells were aseptically grown in sterile 100mm 
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tissue culture dishes to 90% confluence in 
respective growth media. All growth media was 
replaced with serum-free DMEM/F12 media for 48 
hours. Serum-free conditioned media was 
collected, centrifuged at 10,000 rpm for 7 minutes, 
supernatant retrieved and stored at -20°C for use in 
secretome studies. Normal HSG cells cultured in 
the cancer secretome from HTB-41 cells were 
designated as HSG* cells. For all secretome 
experiments, three groups of cells were used – 
normal human salivary gland cells/naïve group 
(HSG), human salivary gland cancer cells/positive 
control group (HTB-41) and normal human 
salivary gland cancer cells treated with cancer 
secretome/experimental group (HSG*). All cell 
culture experiments were carried outin triplicate. 
Protocols 
Immunohistochemistry (IHC): IHC was utilized to 
determine the expression of OPN, BSP and DSP 
in normal and cancerous human salivary gland 
tissue samples. Salivary gland sections were fixed 
in 4% paraformaldehyde and cryosectioned at 10-
12 µm onto glass slides. Tissue sections were 
immunostained with specific antibodies against 
BSP and DSP. Briefly, tissue sections were 
rehydrated through decreasing concentrations of a 
graded ethanol series, endogenous peroxidase 
activity was quenched using 3% hydrogen 
peroxide (Bloxall, Vector Laboratories, 
Burlingame, CA) for 30 minutes, followed by a 
0.07M PBS wash. Tissue sections were then 
blocked with blocking serum, and reacted against 
anti-BSP, anti-DSP or anti-OPN primary 
antibodies (Santa Cruz Biotechnology, Inc., 
Dallas, TX/1:100) overnight at 4˚C. Following a 
0.07M PBS wash, sections were then conjugated 
with biotinylated secondary antibodies for 1 hour. 
Sections were then reacted against an avidin-
biotin complex (ABC kit, Vector Laboratories, 
Burlingame, CA). The ABC complex was then 
reacted against diaminobenzidine/DAB, a 
horseradish peroxidase enzyme for the specific 
antigen being tested. Sections were counterstained 
with Hematoxylin, dehydrated through a graded 
ethanol series, mounted on glass slides and sealed 
with glass coverslips. All immunohistochemistry 
images were acquired using a light microscope 
(Leica DM2500, Leica Microsystems, Buffalo 
Grove, IL). Presence of a water-insoluble brown 
precipitate confirmed localization of the protein of 
interest (Figure 3). 
 
 
 
 
 
 
 
 
Fig. 3. Diagrammatic representation of the immunohistochemistry process  
Protein extraction from HSG and HTB-41 cells: 
To extract protein from HSG and HTB-41 cell 
lines, cells were washed in 1X PBS before adding 
1 ml of Mammalian Protein Extraction Reagent 
(M-PER). Cell plates were scraped and collected 
for 15 minute centrifugation at 4000 rpm. 
Supernatant was utilized for SDS-PAGE and 
Western Immunoblotting. 
SDS-PAGE and Western Blotting: Protein 
estimation was carried out using the RC DC 
protein assay (Bio-Rad, Hercules, CA) and equal 
amounts of protein were resolved by 10% SDS-
PAGE under reducing conditions. After 
electrophoresis, proteins were electrotransferred 
onto nitrocellulose membranes (Bio-Rad, 
Hercules, CA), blocked with 5% non-fat milk in 
1X PBS, and probed with anti-BSP, anti-DSP and 
anti-OPN antibodies (1:500; Santa Cruz 
Biotechnology, Dallas, TX). HRP-conjugated goat 
anti-mouse IgG was used as secondary antibody 
(1:10,000; Sigma-Aldrich, St. Louis, MO) and 
Clarity western ECL (Bio-Rad, Hercules, CA) was 
used as the substrate for HRP detection. 
To determine equal protein loading, each 
membrane was carefully washed, treated for 5 min 
with stripping buffer (Thermo Scientific/Pierce, 
Rockford, IL) to eliminate the previous reaction 
and washed with PBS. Membranes containing 
whole protein and cytoplasmic fractions were 
processed as above with anti-tubulin primary 
antibody (1:10,000; Sigma-Aldrich, St. Louis, 
MO) and HRP-conjugated goat anti-mouse IgG 
secondary antibody (1:10,000; Sigma-Aldrich, St. 
Louis, MO). Experiments were carried out in 
triplicate. 
Immunofluorescence: HSG, HTB-41, and HSG* 
cells were processed for immunofluorescence in 
order to examine morphology. Cells were fixed 
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with 4% Paraformaldehyde, rinsed with 0.07M 
PBS, and permeabilized with 0.01% Triton X-100 
for 15 minutes. Non-specific staining was blocked 
with donkey blocking solution for 45 minutes, then 
primary antibodies were diluted in blocking serum 
and added to the cells overnight at 4°C (1:500). 
The next day, cells were rinsed with 0.07M PBS 
three times, for 10 minutes each. Secondary 
antibodies were then diluted in 0.07M PBS and 
added to the cells for 2 hours at room temperature 
(1:1000). Counterstaining with Rhodamine-
Phalloidin to visualize the actin cytoskeleton, and 
DAPI to stain nuclei were carried out. Cells were 
rinsed again with 0.07M PBS and mounted to glass 
slides with Prolong Gold mounting media. 
Results 
BSP, DSP and OPN are enriched in human 
salivary gland cancer tissue (Aim 1). 
Immunohistochemistry on human salivary gland 
cancer tissue showed enhanced positive reaction 
against BSP, DSP and OPN antibodies as 
compared to normal human salivary gland tissue 
(Figure 4). As expected, the stroma of normal 
salivary gland tissue showed a diffuse brown 
staining for DSP and OPN (Figure 4B, 4C). In 
addition, epithelial cells lining the salivary gland 
ducts showed positive staining, indicating the 
presence of BSP, DSP and OPN (Figure 4A, 4B 
and 4C). 
In contrast to normal tissue, BSP showed a 
stronger reaction in the stroma as well as inside the 
cellular profiles of human salivary gland cancer 
tissue (Figure 4A’). Cancer tissue also showed a 
robust staining against DSP in the stroma and more 
prominently within the cellular profiles of the 
ductal epithelia (Figure 4B’). In tissue stained 
against OPN, the extracellular and intracellular 
expression of OPN was evident (Figure 4C’). 
Tissue sections stained as negative controls did not 
show increased positive staining against BSP, DSP 
or OPN (Figures 4A”, 4B” and 4C”) 
 
Fig. 4. BSP, DSP and OPN are strongly expressed in human salivary gland cancer samples  
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A, A’, A”: Immunohistochemistry images showing 
BSP expression in normal (A), cancer (A’) and 
negative controls (A”). In normal tissue, nuclei 
stain dark purple and there is no positive DAB 
staining evident within the intracellular profiles of 
the acinar cells. The cytoplasm of the ductal 
epithelial cells (green asterisks  indicate ducts) 
show positive brown staining indicating BSP 
expression. In cancer cells, there is cytoplasmic 
expression of BSP in both ductal epithelia (red 
asterisks indicate ducts) and acinar epithelia, as 
well as a diffuse positive DAB expression  in the 
stroma/extracellular compartment. 
B, B’, B”: Immunohistochemistry images showing 
DSP expression in normal (A), cancer (A’) and 
negative controls (A”). In normal tissue, DSP 
expression is seen in the ductal epithelia (green 
asterisks indicate ducts), as well as in the 
stroma/extracellular compartment. The 
extracellular expression of DSP was more evident 
than that seen with BSP. In cancer tissue, a very 
robust DSP expression is seen associated with 
epithelia. Since the adenocarcinoma primarily 
originates from and affects ductal epithelia, all 
cellular profiles show the salivary gland ducts. 
Purple nuclear staining is evident with brown 
staining of the cytoplasm present around the 
nucleus. 
C, C’, C”: Immunohistochemistry images showing 
OPN expression in normal (A), cancer (A’) and 
negative controls (A”). In normal tissue, OPN 
expression is seen primarily as a brown precipitate 
in the cytoplasm of ductal cells (green asterisks  
indicate ducts). At the bottom left and right corners 
of panel C brown DAB staining of adipose tissue is 
evident, as expected. In cancer tissue, strong 
cytoplasmic staining of the ductal cells with a 
prominent purple nucleus is seen. Since the 
adenocarcinoma primarily originates from and 
affects ductal epithelia, all cellular profiles show 
the salivary gland ducts. 
Negative controls of all cancer samples (A”, B”, 
C”) did not show positive expression of BSP, DSP 
or OPN. In the absence of eosin staining, negative 
controls shows a diffuse blueish-purple hue of the 
cytoplasm and the extracellular compartment. 
BSP, DSP and OPN exhibit specific localization in 
human salivary gland cancer cells (Aim 1). 
Immunofluorescence studies against BSP, DSP 
and OPN antibodies were carried out in normal 
human salivary gland cells (HSG) and human 
cancer salivary gland cells (HTB-41), and is 
depicted in Figure 5. BSP, DSP and OPN were 
present in normal HSG cells, as expected. BSP 
specifically co-localized with the actin 
cytoskeleton, and is seen expressed along the actin 
cytoskeleton, as well as outlining the cell profiles  
together with actin (Figure 5; Panel A merge). In 
cancer HTB-41 cells, BSP continued to co-localize 
with actin, and exhibited a presence along the actin 
stress fibers (Figure 5; Panel B merge). 
DSP expression in normal HSG cells was 
cytoplasmic (Figure 5C’). In addition, a discrete 
accumulation of DSP was seen localized as a 
cytoplasmic “cap” in relation to the nucleus 
(Figure 5C” and Panel C merge). In contrast, 
cancer HTB-41 cells showed a robust presentation 
of DSP in the cytoplasm, as a “perinuclear ring” 
(Figure 5D” and Panel D merge). 
OPN in normal HSG cells exhibited a very strong 
cytoplasmic distribution (Figure 5E’), while in 
cancer HTB-41 cells, OPN was very distinctly 
seen to have a robust nuclear presentation (Figure 
5F’ and Panel F merge). 
As evidenced by the actin distribution, the data 
also show that cancer salivary gland cells have a 
very distinct morphology as compared to normal 
salivary gland cells (Figures 5B, 5C, 5D). While 
normal cells exhibit a polyhedral shape, cancer 
cells exhibit a “stellate” configuration as a result of 
the elaborate filopodial extensions that project 
from the cells. 
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Fig. 5. (on opposite page): BSP, DSP and OPN exhibit specific intracellular localizations in normal HSG and 
cancer HTB-41 cells (Scale bar = 5µm) 
A, A’, A”, merge: Representative confocal images 
depict actin cytoskeleton, intracellular localization 
of BSP and nuclei in normal HSG cells. The actin 
cytoskeleton and cortical actin clearly shows the 
normal, expected cell morphology of human 
salivary gland cells. BSP is localized to the cell 
membrane as well as the cytoplasm. The merged 
image shows BSP co-localizing with actin, both in 
the cell membrane, as well as in the cytoskeleton. 
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B, B’, B”, merge: Representative confocal images 
depict actin cytoskeleton, intracellular localization 
of BSP and nuclei in cancer HTB-41 cells. Cell 
morphology in the cancer cells are different from 
that seen in normal salivary gland cells, as 
evidenced by the extensive actin-lined membrane 
extensions or filopodia, giving them a “stellate” 
appearance (white arrows) . BSP continues to be 
associated with the cell membrane and extends 
along the filopodia. In the merged image, the 
strong co-localization between actin and BSP is 
clearly evident. 
C, C’, C”, merge: Representative confocal images 
depict actin cytoskeleton, intracellular localization 
of DSP and nuclei in normal HSG cells. In normal 
HSG cells, DSP is distributed in the cytoplasm, 
and there is an accumulation of DSP towards one 
side of the cell. The merged image clearly 
indicates that in addition to the diffuse cytoplasmic 
distribution of DSP, there is a cytoplasmic 
accumulation that is localized as a “cap” in relation 
to the nucleus. Unlike BSP, DSP is not associated 
with actin. 
D, D’, D”, merge: Representative confocal images 
depict actin cytoskeleton, intracellular localization 
of DSP and nuclei in cancer HTB-41 cells. In 
cancer cells, DSP continues to have a cytoplasmic 
presentation, but the staining is more intense than 
in normal salivary gland cells. Unlike normal cells, 
the cytoplasmic accumulation of DSP is distributed 
as an intense “perinuclear ring”. 
E, E’, E”, merge: Representative confocal images 
depict actin cytoskeleton, intracellular localization 
of OPN and nuclei in normal HSG cells. OPN is 
distributed all throughout the cytoplasm in normal 
HSG cells. Our data show that moderate nuclear 
presentation was seen in few cells. 
F, F’, F”, merge: Representative confocal images 
depict actin cytoskeleton, intracellular localization 
of OPN and nuclei in cancer HTB-41 cells. In 
addition to a cytoplasmic distribution, OPN is seen 
to translocate into the nucleus. 
BSP, DSP and OPN levels are upregulated in 
human salivary gland cancer (Aim 2). 
Western blot analyses to evaluate levels  of BSP, 
DSP and OPN in human salivary gland cancer cells 
(HTB-41) in comparison to normal human salivary 
gland cells (HSG) were carried out. Data were 
analyzed in triplicate, and show that expression 
levels of BSP, DSP and OPN are significantly 
elevated in cancer HTB-41 cells as compared to 
normal HSG cells (Figure 6). 
 
 
Fig. 6. BSP, DSP and OPN levels are significantly elevated in cancer HTB-41 cells. 
Cancer secretome enhances BSP, DSP and OPN expression in normal human salivary gland cells (Aim 3). 
As described earlier, normal human salivary gland cells (HSG) were aseptically cultured in serum-free 
secretome collected from human salivary gland cancer cells (HTB-41) for 24, 48 and 72 hours, and designated 
as HSG* cells. Under the influence of the cancer secretome, BSP expression seemed to be increased in the 
cytoplasm and nuclear compartments of HSG* cells (Figure 7A, 7A’ and 7A”). DSP expression in normal HSG 
cells is localized to the cytoplasm with an intense cytoplasmic accumulation, previously described as a 
“polarized cap” in relation to the nucleus. In contrast, HSG* cells show the perinuclear presentation seen in 
cancer HTB-41 cells (Figure 7B, 7B’ and 7B”). 
Fig. 7 (opposite page). BSP, DSP and OPN expression is enhanced in normal HSG cells following 
exposure to a cancer secretome for 72 hours. Representative confocal images of HSG, HTB-41 and HSG* 
cells depict localization of BSP and DSP. (Scale bar = 5µm) 
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A, A’, A”: Merged confocal images depict the distribution of BSP in normal HSG, cancer HTB-41 and 
cancer secretome-induced HSG* cells. Under the influence of the cancer secretome, a nuclear presentation 
of BSP is seen in HSG* cells. The nuclear translocation of BSP is not evident in cancer HTB-41 cells and 
may be indicative of transformation of normal cells into a cancer phenotype by the influence of specific 
growth factors in the cancer secretome. 
B, B’, B”: In HSG* cells under the influence of the cancer secretome, DSP expression is greatly  
enhanced. 
C, C’, C”: OPN in HSG* cells shows strong nuclear translocation, as compared to that seen in  normal. 
 
In HSG* cells, OPN expression is visible as intense 
nuclear staining, as compared to normal HSG cells 
(Figure 7C, 7C’, 7C”). The changes observed in 
BSP, DSP and OPN expression, indicate that under 
the influence of the cancer secretome, normal HSG 
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cells begin to more closely mirror the expression 
seen in cancer cells. 
As described previously, in addition to the altered 
expression of BSP, DSP and OPN in HSG* cells, 
cell morphology was also distinctly different from 
normal. HSG* cells exhibited the more “stellate” 
cell morphology with associated membrane 
extensions that are typically seen in cancer cells 
(Figure 7A”, 7B”, 7C”). 
Discussion 
SIBLINGs are a family of five proteins, that are 
encoded by identically oriented tandem genes 
located on chromosome 4 (BSP, DSP, DMP1, OPN 
and MEPE). They are small, soluble, RGD motif 
containing, integrin-binding ligands, and are unique 
from larger extracellular matrix proteins such as  
fibronectin and collagen. Four of the five members 
of this protein family (BSP, DSP, DMP1 and OPN) 
have been shown to be present in mineralized 
matrices of bone and dentin, while varying 
combinations of all five SIBLING proteins have 
been shown to be significantly upregulated in 
various epithelial cancers, which metastasize to 
bone (Bellahcene et al., 2008; Ogbureke and 
Fisher, 2004, , 2007; Suzuki et al., ; Trueb et al., 
2007). 
A previous study evaluating human gland tissue 
has shown that SIBLINGs are expressed in 
metabolically active, high energy-requiring sweat 
gland ducts as compared to metabolically inactive 
lacrimal ducts (Ogbureke and Fisher, 2007). Major 
salivary glands produce approximately 700 to 1200 
ml of saliva daily. Primary saliva that is produced 
by the acinar cells is isotonic as compared to 
plasma. The striated cells of the salivary gland 
ducts modify the primary saliva by removing 
sodium and chloride ions from it, and secreting 
potassium and bicarbonate ions into it. The altered 
secretion is hypotonic and is referred to as 
secondary saliva. To support this high-energy 
requiring metabolic activity of the ducts, salivary 
glands are supplied by a very rich vascular supply, 
almost twenty times as much as the blood flow to 
skeletal muscle. Our s tudies of normal human 
salivary gland tissue show evidence of BSP, DSP 
and OPN expression and could indicate the high 
metabolic activity that typically characterizes the 
ductal cells of salivary glands. Evaluation of the 
normal salivary gland cell line, HSG, also confirms 
that BSP, DSP and OPN have very specific and 
unique intracellular localizations. In addition, 
protein quantification in the current study also 
shows that there is not a complete lack of BSP, 
DSP and OPN in normal salivary gland cells; 
rather, a baseline level of BSP, DSP and OPN is 
maintained, presumably to regulate the 
extraordinarily high metabolic requirements of the 
salivary gland ductal cells. 
In contrast to normal human salivary gland tissue 
and cells, our data show that salivary gland cancer 
exhibits a more robust expression of BSP, DSP and 
OPN. In vitro studies of breast cancer cells have 
shown that BSP is capable of increasing cell 
proliferation (Sung et al., 1998). Human breast 
cancer cells transfected with BSP and injected into 
the mammary fat pad of nude mice stimulated 
migration, invasion and growth of primary and 
secondary tumors (Sharp et al., 2004). Elevated 
levels of BSP have also been found in cancers that 
have a high propensity to metastasize to bone, such 
as cancers of the breast (Bellahcene et al., 1996a; 
Bellahcene et al., 1996b; Bellahcene et al., 1994), 
prostate (Waltregny et al., 1998) and lung 
(Bellahcene et al., 1997). Our evaluation of human 
salivary gland cancer issue as well as the human 
salivary gland cancer cell line, HTB-41, indicate 
strong and very specific intracellular expression of 
BSP. In tissue samples, BSP was found to be 
localized to the extracellular matrix/stroma, as well 
as had an intracellular presentation of both acinar 
and ductal cells. 
Confocal microscopy studies, as well as previous 
scanning electron microscopy studies have revealed 
that cancer HTB-41 cells exhibit a variant 
morphology and cytoarchitecture as compared to 
normal salivary gland cells (Figure 10). 
Specifically, salivary gland cells transform from a 
more rounded/polyhedral shape to a more “stellate” 
morphology with numerous membrane extensions 
extending in multiple directions. In addition, 
normal salivary gland cells grow as a cohesive 
“sheet” of cells, while cancer cells tend to grow in 
clumps/groups. The known biological activities of 
BSP, namely its role in cancer metastasis, coupled 
with co-localization with the actin cytoskeleton 
could indicate a potential role for BSP in promoting 
cell spreading, and initiating cell migration via 
filopodial extensions in human salivary gland 
cancers. 
Dentin sialophosphoprotein (DSPP) and its cleaved 
products, namely, DPP/dentin phosphoprotein and 
DSP/dentin sialoprotein play important roles in 
biomineralization (Prasad et al.,; Sreenath et al., 
2003; Verdelis et al., 2008; Xiao et al., 2001). In 
addition to its expression in mineralized tissue such 
as bone, 
Interestingly, the immunofluorescence data closely 
mirrors the presentation seen in the tissue sections. 
In cancer HTB-41 cells, DSP expression is very 
clearly visualized as a “polar cap” located in the 
cytoplasm, but in close proximity to the nucleus. In 
addition, levels of DSP in cancer HTB-41 cells 
were significantly elevated as compared to normal 
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salivary gland cells. Although DSP has very 
specific roles in mineralized tissue, its roles in non-
mineralized tissue have not been clearly elucidated 
yet. In non-mineralized tissues, it has been 
suggested that DSP is devoid of carbohydrate 
moieties (Prasad et al.), thus indicating a very 
different role for DSP in non-mineralized tissue as 
compared to mineralized tissue. Therefore, in 
salivary gland cancers, DSP expression could 
indicate important roles that include regulation of 
cell adhesion and cell migration. In addition, DSP 
has been shown to have a potential role in 
maintenance of blood vessel homeostasis and stem 
cell differentiation. In salivary gland cancers, DSP 
expression could potentially play a role in 
supporting angiogenesis and activating the stem 
cell niche in salivary gland ducts, thus promoting 
cancer progression and metastasis. 
Osteopontin (OPN) is a multifunctional SIBLING 
protein which is highly expressed in bone, and also 
expressed in macrophages, endothelial cells and 
smooth muscle cells (Mazzali et al., 2002; O'Brien 
et al., 1994). In normal bone tissue, OPN is 
expressed by both osteoclasts and osteoblasts, and 
plays an important role in the regulation of bone 
remodeling. OPN expression is also prominent in 
tissues showing dystrophic or pathological 
calcifications such as arterial calcified plaques 
(Hirota et al., 1993; O'Brien et al., 1995; Srivatsa et 
al., 1997) and in the kidneys (Hess, 1994; Shiraga 
et al., 1992); in these tissues OPN acts as an 
inhibitor to prevent or limit calcifications. OPN is 
also a cell survival factor, and inhibits apoptosis 
(Ophascharoensuk et al., 1999). It is also an 
important molecule in wound healing and tissue 
regeneration. In addition to its diverse roles in 
normal cell biology, OPN is also important in 
tumor cell biology. In fact, OPN was first isolated 
from epithelial cells that had undergone malignant 
transformation (Senger et al., 1983; Senger et al., 
1989). OPN has been shown to increase 
proliferation of cancer cells in a mouse model of 
prostate cancer (Khodavirdi et al., 2006). OPN also 
has critical roles in cell invasion that eventually can 
progress to cellular metastasis in cancer. 
Specifically, OPN has the ability to increase 
invasiveness of cancer cells that allow these cells to 
then invade into blood vessels (Khodavirdi et al., 
2006). In vitro migration of several cancer cell 
lines, including skin, breast and blood have also 
been reported (Caers et al., 2006; Hayashi et al., 
2007; Khan et al., 2005). The known biological 
activities of OPN thus help in the promotion of 
metastatic properties when expressed in cancer 
cells. Although OPN has been shown to be 
upregulated (Ogbureke et al., 2007) in oral cancers, 
a systematic evaluation of its cellular distribution 
and expression in salivary gland cancers is as yet 
lacking. Our data provide evidence of the 
expression of OPN in human salivary gland cancer 
tissue as well as in a human cancer HTB-41 cell 
line. In tissue samples, OPN shows a very robust 
intracellular staining that completely fills the 
cytoplasm. In the confocal images, a very clear 
cytoplasmic presentation of OPN is evident, along 
with a distinct nuclear translocation. Further 
analyses of nuclear versus cytoplasmic fractions are 
warranted to confirm elevated levels of OPN in the 
nuclear fraction as compared to the cytoplasmic 
fraction. OPN levels in cancer HTB-41 cells also 
showed a significant increase as compared to 
normal human salivary gland cells. Our data thus 
indicate that OPN, the first SIBLING protein that 
was found to be overexpressed in cancer (Senger et 
al., 1983), is in fact upregulated in human salivary 
gland cancers. Thus, very similar to BSP, OPN 
expression in cancer cells may not be restricted to 
cancer cells that metastasize to bone alone, but 
rather to cancer cells that have a general malignant 
phenotype. A previous study by Junaid et al, 2006 
demonstrated that OPN translocates into the 
nucleus via an exportin-1-dependent mechanism 
(Junaid et al., 2007). Furthermore, this 
translocation concurs with the S phase and thus 
increases cellular OPN in the G2/M phase, while 
interacting with polo-like-kinase-1, a proto-
oncogene often overexpressed in tumors (Junaid et 
al., 2007). The nuclear translocation of OPN into 
the nucleus could potentially indicate regulation of 
cancer cell migration and tissue invasion at a 
transcriptional level and warrants further studies. 
The observations that confirmed 
upregulation of BSP, DSP and OPN in salivary 
gland cancer as opposed to normal human salivary 
gland cells, led to the hypothesis that the cancer 
microenvironment could potentially influence 
behavior of normal cells. Therefore, cancer 
secretome was collected and normal human 
salivary gland cells were cultured in the cancer 
secretome to understand the role of the cancer 
secretome in BSP, DSP and OPN expression. 
Secreted factors are key mediators of cell-cell 
communication, and are responsible for regulating 
cell proliferation, cell migration, cell invasion, and 
evasion of apoptosis and several other hallmarks of 
cancer by cell signaling. The cancer secretome has 
multiple factors that can contribute towards various 
cellular functions, the goal of our study was to 
evaluate if the cancer secretome, with all its variant 
factors could potentially influence the expression of 
BSP, DSP and OPN. Future studies will evaluate 
the cancer secretome itself to identify key factors 
that may have a role in regulating SIBLING 
expression. Our study shows that under the 
influence of the human salivary gland cancer 
secretome, normal human salivary gland cancer 
cells begin to express BSP, DSP and OPN in a 
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similar phenotypic manner as seen in the cancer 
cells. Specifically, BSP and DSP levels are 
elevated significantly as compared to normal 
salivary gland cells, and intracellular localization of 
BSP, DSP and OPN are more similar to cancer 
HTB-41 cells than normal HSG cells. Our study 
supports the increasingly evident fact that cancer 
cells do not act in isolation during cancer 
progression and metastasis. Rather, primary tumor 
cells interact with non-transformed cells to create a 
microenvironment that is conducive to cancer cell 
survival, progression and metastasis. Although this 
close interaction between cancer cells and non-
transformed cells can enhance cancer progression 
and increase malignancy, identifying key 
membrane and intracellular players such as the 
SIBLING proteins will allow us to develop 
strategic therapies targeting either specific factors 
in the cancer secretome or specific downstream 
molecules that are involved in the transmission of 
cell signals. 
The current study thus provides valuable 
information regarding the expression of BSP, DSP 
and OPN in human salivary gland cancers; and for 
the first time, it specifically outlines intracellular 
localizations of these proteins. Although further 
studies are warranted, the data show a clear role of 
the cancer secretome in maintaining “cancer-ness”, 
thus potentially promoting specific hallmarks of 
metastasis namely cell proliferation, cell migration, 
cell invasion and cell survival through downstream 
cell signaling pathways mediated via SIBLING 
proteins. 
Human salivary glands offer a unique opportunity 
in future studies to identify other SIBLINGs or 
factors in the cancer secretome, which may be 
linked to activation and upregulation of SIBLING 
proteins. Furthermore, the future documentation of 
key membrane and intracellular players interacting 
with SIBLINGs in the cancer secretome may offer 
novel evidence leading to answers regarding 
therapeutic targeting. In regards to OPN, future 
studies may focus on its expression in nuclear and 
cytoplasmic fragments, as well as its mechanism of 
translocation into the nucleus. Studying the roles of 
SIBLING proteins will not merely give rise to 
forthcoming studies, but proposition additional data 
leading to therapeutic targeting. 
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